A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB study

被引:8
|
作者
Qurashi, Inti [1 ]
Chaudhry, Imran B. [2 ,3 ,4 ]
Khoso, Ameer B. [4 ]
Husain, Muhammad Omair [5 ,6 ]
Hafeez, Danish [7 ]
Kiran, Tayyeba [4 ]
Lane, Steven [8 ]
Naqvi, Haider A. [9 ]
Minhas, Fareed A. [10 ]
Nizami, Asad Tamizuddin [10 ]
Razzaque, Bushra [10 ]
Bokhari, Sumira Qambar [11 ]
Yung, Alison R. [12 ,13 ]
Deakin, Bill [14 ]
Husain, Nusrat [2 ,15 ]
机构
[1] Univ Liverpool, Inst Populat Hlth, Liverpool, England
[2] Univ Manchester, Div Psychol & Mental Hlth, Manchester, England
[3] Ziauddin Univ, Dept Psychiat, Karachi, Pakistan
[4] Pakistan Inst Living & Learning, Karachi, Pakistan
[5] Ctr Addict & Mental Hlth, Toronto, ON, Canada
[6] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[7] Homerton Univ Hosp, London, England
[8] Univ Liverpool, Inst Translat Med, Liverpool, England
[9] Dow Univ Hlth Sci, Dept Psychiat, Karachi, Pakistan
[10] Rawalpindi Med Univ, Inst Psychiat, Rawalpindi, Pakistan
[11] Serv Inst Med Sci, Dept Psychiat & Behav Sci, Lahore, Pakistan
[12] Univ Melbourne, Ctr Youth Mental Hlth, Parkville, Vic, Australia
[13] Orygen, Parkville, Vic, Australia
[14] Univ Manchester, Sch Biol Sci, Div Neurosci & Expt Psychol, Manchester, England
[15] Mersey Care NHS Fdn Trust, Prescot, England
关键词
Early intervention; Psychosis; Minocycline; Omega-3; At-risk mental state; Inflammation; POLYUNSATURATED FATTY-ACIDS; PSYCHOTIC DISORDERS; YOUNG-PEOPLE; SCHIZOPHRENIA; VERSION; ONSET;
D O I
10.1016/j.bbi.2023.10.025
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Inflammatory mechanisms are thought to contribute to the onset of psychosis in persons with an at -risk mental state (ARMS). We investigated whether the anti-inflammatory properties of minocycline and omega -3 polyunsaturated fatty acids (omega-3), alone or synergistically, would prevent transition to psychosis in ARMS in a randomised, double-blind, placebo-controlled trial in Pakistan.Methods: 10,173 help-seeking individuals aged 16-35 years were screened using the Prodromal Questionaire-16. Individuals scoring 6 and over were interviewed using the Comprehensive Assessment of At-Risk Mental States (CAARMS) to confirm ARMS. Participants (n = 326) were randomised to minocycline, omega-3, combined minocycline and omega-3 or to double placebo for 6 months. The primary outcome was transition to psychosis at 12 months.Findings: Forty-five (13.8 %) participants transitioned to psychosis. The risk of transition was greater in those randomised to omega-3 alone or in combination with minocycline (17.3.%), compared to 10.4 % in those not exposed to omega-3; a risk-ratio (RR) of 1.67, 95 % CI [0.95, 2.92] p = 0.07. The RR for transitions on mino-cycline vs. no minocycline was 0.86, 95 % CI [0.50, 1.49] p > 0.10. In participants who did not become psychotic, CAARMS and depression symptom scores were reduced at six and twelve months (mean CAARMS difference = 1.43; 95 % CI [0.33, 1.76] p < 0.01 in those exposed to omega-3. Minocycline did not affect CAARMS or depression scores.Interpretation: In keeping with other studies, omega-3 appears to have beneficial effects on ARMS and mood symptom severity but it increased transition to psychosis, which may reflect metabolic or developmental consequences of chronic poor nutrition in the population. Transition to psychosis was too rare to reveal a preventative effect of minocycline but minocycline did not improve symptom severity. ARMS symptom severity and transition to psychosis appear to have distinct pathogeneses which are differentially modulated by omega-3 supplementation.Funding: The study was funded by the Stanley Research Medical Institute.
引用
收藏
页码:609 / 616
页数:8
相关论文
共 50 条
  • [21] Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment
    Chaudhry, Imran B.
    Hallak, Jaime
    Husain, Nusrat
    Minhas, Fareed
    Stirling, John
    Richardson, Paul
    Dursun, Serdar
    Dunn, Graham
    Deakin, Bill
    JOURNAL OF PSYCHOPHARMACOLOGY, 2012, 26 (09) : 1185 - 1193
  • [22] Role of Omega-3 fatty acids in preventing metabolic disturbances in patients on olanzapine plus either sodium valproate or lithium: a randomized double-blind placebo-controlled trial
    Faghihi, Toktam
    Jahed, Adel
    Mahmoudi-Gharaei, Javad
    Sharifi, Vandad
    Akhondzadeh, Shahin
    Ghaeli, Padideh
    DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 20
  • [23] Omega-3 fatty acids does not affect physical activity and body weight in primary school children - a double-blind randomized placebo-controlled trial
    Svensson, V.
    Johansson, E.
    Fischer, M.
    Deng, S. L.
    Hagstromer, M.
    Danielsson, P.
    SCIENTIFIC REPORTS, 2018, 8
  • [24] Minocycline as Adjunctive Treatment to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial
    Ghaleiha, Ali
    Alikhani, Rosa
    Kazemi, Mohammad-Reza
    Mohammadi, Mohammad-Reza
    Mohammadinejad, Payam
    Zeinoddini, Atefeh
    Hamedi, Mehdi
    Shahriari, Mona
    Keshavarzi, Zahra
    Akhondzadeh, Shahin
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2016, 26 (09) : 784 - +
  • [25] Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial
    Fekadu, Abebaw
    Mesfin, Miraf
    Medhin, Girmay
    Alem, Atalay
    Teferra, Solomon
    Gebre-Eyesus, Tsehaysina
    Seboxa, Teshale
    Assefa, Abraham
    Hussein, Jemal
    Lemma, Martha T.
    Borba, Christina
    Henderson, David C.
    Hanlon, Charlotte
    Shibre, Teshome
    TRIALS, 2013, 14
  • [26] Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial
    Abebaw Fekadu
    Miraf Mesfin
    Girmay Medhin
    Atalay Alem
    Solomon Teferra
    Tsehaysina Gebre-Eyesus
    Teshale Seboxa
    Abraham Assefa
    Jemal Hussein
    Martha T Lemma
    Christina Borba
    David C Henderson
    Charlotte Hanlon
    Teshome Shibre
    Trials, 14
  • [27] The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study
    Chiu, Chih-Chiang
    Su, Kuan-Pin
    Cheng, Tsung-Chi
    Liu, Hsing-Cheng
    Chang, Ching-Jui
    Dewey, Michael E.
    Stewart, Robert
    Huang, Shih-Yi
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2008, 32 (06): : 1538 - 1544
  • [28] A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of an Omega-3 Fatty Acid Supplement in Patients With Predialysis Chronic Kidney Disease
    Bunout, Daniel
    Barrera, Gladys
    Hirsch, Sandra
    Lorca, Eduardo
    JOURNAL OF RENAL NUTRITION, 2021, 31 (01) : 64 - 72
  • [29] A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism
    Mankad, Deepali
    Dupuis, Annie
    Smile, Sharon
    Roberts, Wendy
    Brian, Jessica
    Lui, Toni
    Genore, Lisa
    Zaghloul, Dina
    Iaboni, Alana
    Marcon, Peggy Margaret A.
    Anagnostou, Evdokia
    MOLECULAR AUTISM, 2015, 6
  • [30] The Effect of Omega-3 Fatty Acids on ARDS: A Randomized Double-Blind Study
    Parish, Masoud
    Valiyi, Farnaz
    Hamishehkar, Hadi
    Sanaie, Sarvin
    Jafarabadi, Mohammad Asghari
    Golzari, Samad E. J.
    Mahmoodpoor, Ata
    ADVANCED PHARMACEUTICAL BULLETIN, 2014, 4 : 555 - 561